The antibody targeting HTRA1 can greatly neutralize the HTRA1’s enzymatic activity and the ability to stimulate inflammation indicating that HTRA1 can be the potential target for treating wet AMD. The gene discussed is HTRA1; the disease is wet macular degeneration.